Bioinformatics, Disease and Virus - Drug Discovery Digest

Advancing vaccine design: potential of peptide mimicry

Drug Target Review

AUGUST 11, 2023

In a new development, a recent paper published in Biology Methods & Protocols by Oxford University Press has highlighted a promising avenue for enhancing vaccine efficacy against infectious pathogens like the COVID-19 virus. Since December 2019, SARS-CoV-2 (COVID-19) infection has become a worldwide urgent public health concern.

Vaccine

Vaccine Immune Response Bioinformatics Virus

Q&A: How Terra became a backbone of public health pathogen surveillance

Broad Institute

SEPTEMBER 30, 2024

Today, about a third of Broad’s Terra users are from the public health workforce; in the US, 76 state and local public health labs use the platform for preventing and monitoring infectious disease spread in their communities. This was true in the US and all the more in the Global South, where the burden of infectious disease is the highest.

Bioinformatics

Bioinformatics Disease Engineering Virus

A new viral surveillance system in West Africa is showing the world how to prevent the next pandemic

Broad Institute

APRIL 25, 2024

He started to imagine how the deadly and contagious disease, if confirmed, might spread to half the city’s population. Eight of the 20 patients died, but the spread of the disease in Nigeria stopped there. Blood and urine samples from the man were waiting for Happi in his lab. Happi felt chilled. They called the idea Sentinel.

Virus

Virus Hospitals Disease Government

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

In Silico Modeling Unveils a New Era in Rare Disease Drug Development

The Premier Consulting Blog

JUNE 18, 2023

One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases. However, with rare diseases there may be no available treatments that could serve as SoC or active control in a clinical trial and assigning patients to placebo may be unethical.

Drug Development

Drug Development Disease Clinical Trials Drugs

Not all neoantigens are created equal

Drug Target Review

DECEMBER 28, 2023

Recent advances in bioinformatics show clonal neoantigens are the best targets for immunotherapy, as I will elucidate below. Patients with high numbers of clonal neoantigens show improved disease-free survival. These mutations are called clonal mutations or clonal neoantigens.

Bioinformatics

Bioinformatics Immune Response DNA Vaccine

Defense-Forward Biosecurity

Codon

AUGUST 27, 2024

Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. Sometimes, though, novel diseases do emerge, and as COVID-19 demonstrated, they can surprise us. This is the third essay of four in our pandemic mini-issue.

DNA

DNA Laboratories Hospitals Virus

Monkey Embryos Grow to 25 Days — No Womb Required

Codon

MAY 15, 2023

Early targets may include sickle-cell disease, Friedrich’s ataxia, and cystic fibrosis. Bioinformatics. Bioinformatics. But prime editors also have a couple of issues: They cause some off-target changes in the genome, and they are physically big. Nature Communications. grams per liter titer. Nature Biotechnology.

DNA

DNA Bioinformatics Engineering Virus

Monkey Embryos Grow to 25 Days — No Womb Required

Codon

MAY 15, 2023

Early targets may include sickle-cell disease, Friedrich’s ataxia, and cystic fibrosis. Bioinformatics. Bioinformatics. But prime editors also have a couple of issues: They cause some off-target changes in the genome, and they are physically big. Nature Communications. grams per liter titer. Nature Biotechnology.

DNA

DNA Bioinformatics Engineering Virus

Can Global Genomic Surveillance Forecast the Next Pandemic?

PLOS: DNA Science

MAY 16, 2024

These factors are converging to enable both identification of novel infectious diseases as well as microbial resistance, before these threats can impact public health, write a team from the European Society for Clinical Microbiology and Infectious Diseases in Frontiers in Science. COVID clearly caught us off guard.

Virus

Virus DNA RNA Vaccine

WHO launches global network to detect and prevent infectious disease threats

The Pharma Data

MAY 22, 2023

WHO launches global network to detect and prevent infectious disease threats WHO and partners are launching a global network to help protect people from infectious disease threats through the power of pathogen genomics. New, more transmissible variants of the virus would not have been as quickly identified.

Disease

Disease Bioinformatics Virus Vaccine

Codon Digest: GPT-4 Controls a Robot

Codon

APRIL 16, 2023

Compact gene editors , called enOsCas12f1 and enRhCas12f1, are smaller than many existing Cas proteins and can thus be more easily delivered in a single virus for gene therapies. BMC Bioinformatics. Read An RNA-based system to study hepatitis B virus replication and evaluate antivirals. The Lancet Infectious Diseases.

Engineering

Engineering DNA RNA Science

Early evidence and emerging trends: How AI is shaping drug discovery and clinical development

Drug Target Review

APRIL 11, 2025

Leveraging vast genomic datasets alongside other data and multimodal language models , this approach offers a deeper understanding of disease biology and enables more precise patient selection. These approaches may also have important implications in the development of novel drugs to treat a range of eye diseases, including glaucoma.

Clinical Development

Clinical Development Drugs Pharmaceuticals Clinical Trials

Is That DNA Dangerous?

Codon

AUGUST 28, 2024

A concerned employee at a laboratory supply company had called the Centers for Disease Control, or CDC, after fielding repeated calls from Harris asking when his samples of plague would arrive in the mail. It wasn’t illegal, however, for Harris to order the vials of deadly bacteria that Ohio police officers later found in his car.

DNA

DNA Bioinformatics Virus Government

Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

The Pharma Data

SEPTEMBER 1, 2020

“Alongside our industry-leading collaborators, we are investigating novel endpoints, brain volume and cognition, which may help to further our understanding of the safety and efficacy profile of Zeposia and can advance transformational science for multiple sclerosis patients experiencing this unpredictable, debilitating disease.”.

Treatment

Treatment Clinical Trials Trials Disease

Drug Discovery Digest

Advancing vaccine design: potential of peptide mimicry

Q&A: How Terra became a backbone of public health pathogen surveillance

Webinars

Trending Sources

A new viral surveillance system in West Africa is showing the world how to prevent the next pandemic

Webinars

In Silico Modeling Unveils a New Era in Rare Disease Drug Development

Not all neoantigens are created equal

Defense-Forward Biosecurity

Monkey Embryos Grow to 25 Days — No Womb Required

Monkey Embryos Grow to 25 Days — No Womb Required

Can Global Genomic Surveillance Forecast the Next Pandemic?

WHO launches global network to detect and prevent infectious disease threats

Codon Digest: GPT-4 Controls a Robot

Early evidence and emerging trends: How AI is shaping drug discovery and clinical development

Is That DNA Dangerous?

Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Stay Connected